Profile data is unavailable for this security.
About the company
OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Company’s product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Company’s subsidiaries include Curetis GmbH and Ares Genetics GmbH.
- Revenue in USD (TTM)3.07m
- Net income in USD-26.16m
- Incorporated2001
- Employees100.00
- LocationOpGen Inc9717 Key West Avenue, Suite 100ROCKVILLE 20850United StatesUSA
- Phone+1 (301) 869-9683
- Fax+1 (301) 869-9684
- Websitehttps://opgen.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMAC Holdings Inc | 0.00 | -6.48m | 4.25m | 2.00 | -- | -- | -- | -- | -5.82 | -8.47 | 0.00 | -0.6554 | 0.00 | -- | -- | 0.00 | -105.93 | -48.88 | -332.19 | -70.25 | -- | -- | -- | -97.63 | -- | -30.07 | -- | -- | -- | -- | 45.27 | -- | -- | -- |
| Dror Ortho-Design Inc | 0.00 | -3.57m | 4.46m | 4.00 | -- | 1.41 | -- | -- | -0.0091 | -0.0091 | 0.00 | 0.0064 | 0.00 | -- | -- | -- | -202.45 | -140.50 | -292.06 | -- | -- | -- | -- | -118,188.00 | -- | -- | 0.00 | -- | -- | -- | -1,896.02 | -- | -- | -- |
| Assure Holdings Corp | 255.00k | -21.45m | 4.55m | 95.00 | -- | -- | -- | 17.84 | -3.80 | -4.60 | 0.055 | -2.28 | 0.0161 | -- | 0.0272 | 2,684.21 | -135.04 | -35.15 | -937.78 | -46.37 | -860.39 | 37.14 | -8,410.59 | -116.06 | -- | -5.92 | -- | -- | -45.86 | -55.62 | 6.19 | -- | -- | -- |
| Greenbrook TMS Inc | 80.08m | -68.03m | 4.90m | 629.00 | -- | -- | -- | 0.0612 | -2.21 | -2.21 | 2.48 | -1.06 | 1.07 | -- | 6.67 | 127,319.30 | -91.88 | -51.23 | -176.23 | -74.15 | 44.96 | 45.93 | -85.75 | -62.45 | -- | -2.29 | 1.72 | -- | 32.39 | 38.06 | -149.38 | -- | -22.47 | -- |
| OpGen Inc | 3.07m | -26.16m | 5.93m | 100.00 | -- | 1.76 | -- | 1.93 | -6.51 | -6.51 | 0.55 | 0.2673 | 0.1202 | 2.91 | 5.64 | 30,702.30 | -102.41 | -79.05 | -196.63 | -110.12 | 6.62 | 22.60 | -852.12 | -706.29 | 0.1809 | -7.53 | 0.7746 | -- | -39.45 | -4.08 | 11.17 | -- | 16.36 | -- |
| Selectis Health Inc | 36.78m | -4.00m | 6.13m | 574.00 | -- | -- | -- | 0.1668 | -1.31 | -1.31 | 12.04 | -0.9663 | 0.8846 | -- | 14.72 | 64,081.97 | -9.55 | -3.03 | -13.65 | -3.58 | -- | -- | -10.80 | -4.84 | -- | -4.12 | 1.09 | -- | -9.40 | 58.97 | -64.93 | -- | -47.72 | -- |
| Interpace Biosciences Inc | 40.21m | 1.11m | 6.17m | 108.00 | 5.65 | -- | 2.89 | 0.1535 | 0.2495 | 0.1769 | 9.21 | -3.48 | 2.77 | 13.31 | 8.03 | 372,342.60 | 7.67 | -38.19 | -- | -69.73 | 59.44 | 49.44 | 2.77 | -41.01 | 0.5205 | 2.78 | -- | -- | 26.31 | 12.93 | 118.96 | -- | 0.9184 | -- |
| Mangoceuticals Inc | 731.49k | -9.21m | 6.24m | -- | -- | 7.30 | -- | 8.52 | -0.6158 | -0.6158 | 0.0467 | 0.0362 | 0.7122 | -- | -- | -- | -896.99 | -- | -1,164.35 | -- | 58.99 | -- | -1,259.41 | -- | 3.79 | -- | 0.00 | -- | 8,082.22 | -- | -361.07 | -- | -- | -- |
| Biocorrx Inc | 89.17k | -3.77m | 6.61m | 5.00 | -- | -- | -- | 74.15 | -0.4532 | -0.4532 | 0.0107 | -1.13 | 0.1543 | -- | 0.7353 | -- | -652.63 | -291.68 | -- | -- | 59.64 | 67.13 | -4,228.44 | -3,208.40 | -- | -4.22 | -- | -- | -58.31 | -25.04 | 13.79 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Chase Investment Counsel Corp.as of 31 Mar 2024 | 331.89k | 3.31% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 66.00k | 0.66% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 53.28k | 0.53% |
| Virtu Americas LLCas of 31 Dec 2023 | 40.38k | 0.40% |
| Geode Capital Management LLCas of 31 Dec 2023 | 36.76k | 0.37% |
| Citadel Securities LLCas of 31 Dec 2023 | 36.38k | 0.36% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 16.04k | 0.16% |
| Two Sigma Securities LLCas of 31 Dec 2023 | 12.10k | 0.12% |
| Tower Research Capital LLCas of 31 Dec 2023 | 7.24k | 0.07% |
| Qube Research & Technologies Ltd.as of 31 Dec 2023 | 200.00 | 0.00% |
